Study of Bone Marrow Samples From Patients With Acute Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00897559|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : May 17, 2017
RATIONALE: Studying the genes expressed in samples of bone marrow from patients with cancer may help doctors identify biomarkers related to cancer.
PURPOSE: This research study is looking at bone marrow samples from patients with acute leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: gene expression analysis Genetic: mutation analysis Genetic: polymorphism analysis Genetic: protein analysis Other: flow cytometry Other: laboratory biomarker analysis|
- To perform high throughput sequencing of a set of megakaryocyte specific transcription factors, tyrosine kinases, and Src kinases in DNA isolated from bone marrow specimens of adults with acute megakaryoblastic leukemia (AMKL).
- To assay the ability of Src kinase inhibitors (SU6656, dasatinib) to induce differentiation of AMKL blasts in these patients.
OUTLINE: DNA from previously collected bone marrow samples are sequenced to analyze genes associated with transcription factors (GATA1, GATA2, SCL, FOG-1, ETS1, ETS2, ERG, FLI-1, GABP, HOXA11, NF-E2, and RUNX1), tyrosine kinases (JAK2, JAK3, and c-MPL), and Src family kinases (LYN, FYN, and HCK) and compared with control DNA. Using bioinformatics, gene alterations are compared to known polymorphisms and subsequent changes in the amino acid sequence of the encoded protein. Subsequent assays assess the effect on proliferation and differentiation and in vitro studies evaluate the consequences of mutations on transcription factor and kinase activity abilities. The effect of SU6656 and dasatinib on cell death and polyploidization is evaluated by flow cytometry and compared with control DNA.
|Study Type :||Observational|
|Actual Enrollment :||40 participants|
|Official Title:||Identifying the Genetic Basis of Adult AMKL|
|Study Start Date :||July 3, 2008|
|Actual Primary Completion Date :||November 11, 2009|
|Actual Study Completion Date :||November 11, 2009|
- Correlation of gene mutations with adult acute megakaryoblastic leukemia (AMKL) [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00897559
|Study Chair:||John Crispino, PhD||Robert H. Lurie Cancer Center|